Intelligent Bio Solutions Inc. has released its unaudited financial results for the three and nine months ended March 31, 2025. The company reported revenue of $728,867 for the three months ended March 31, 2025, down from $823,800 during the same period in 2024. For the nine months ended March 31, 2025, revenue totaled $2.209 million, compared to $2.384 million for the same period in the previous year. The company also reported a comprehensive loss of $2.435 million for the three months ended March 31, 2025, a decrease from the $3.131 million loss reported for the same period in 2024. For the nine-month period, the comprehensive loss was $7.313 million, slightly lower than the $7.482 million loss recorded in the previous year. Intelligent Bio Solutions Inc. cited selling, general, and administrative expenses of $2.408 million for the three months ended March 31, 2025, compared to $2.426 million for the same period in 2024. For the nine-month period, these expenses were $6.166 million, down from $6.588 million in the previous year. The company's gross profit for the three months ended March 31, 2025, was $341,368, up from $178,489 during the same period in 2024. For the nine months ended March 31, 2025, the gross profit was $911,282, compared to $610,068 in the previous year. Intelligent Bio Solutions Inc. noted no significant updates regarding its business operations beyond the financial results disclosed.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。